New hope for Hard-to-Treat prostate cancer?
NCT ID NCT04631744
First seen Jan 04, 2026 · Last updated Apr 24, 2026 · Updated 13 times
Summary
This study tested the drug cabozantinib in men with a type of advanced prostate cancer that no longer responds to hormone therapy. The goal was to see if the drug could shrink tumors or slow the disease, especially in men with certain genetic changes or cancer spread to the liver. Only 4 men took part, and the study is now complete.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Weill Cornell Medicine
New York, New York, 10065, United States
Conditions
Explore the condition pages connected to this study.